LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Начало・Списък с акции・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Затворен

СекторЗдравеопазване

21.22 -3.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

21.03

Максимум

21.48

Ключови измерители
By Trading Economics
Приходи	-29M -11M
Продажби	-24M 105M
EPS	-0.09
Марж на печалбата	-10.717
Служители	354
EBITDA	-31M -8.5M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+64.2% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-252M 2.7B
Предишно отваряне	24.37
Предишно затваряне	21.22

Настроения в новините

By Acuity

31%

69%

67 / 344 Класиране в Healthcare

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.06.2026 г., 19:20 ч. UTC

Значими двигатели на пазара

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

6.06.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

6.06.2026 г., 08:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.06.2026 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.06.2026 г., 00:14 ч. UTC

Придобивния, сливания и поглъщания

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5.06.2026 г., 21:27 ч. UTC

Печалби

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.06.2026 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5.06.2026 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5.06.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

5.06.2026 г., 19:26 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.06.2026 г., 19:26 ч. UTC

Пазарно говорене

Hog Futures Tumble to Close Week -- Market Talk

5.06.2026 г., 19:10 ч. UTC

Пазарно говорене

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5.06.2026 г., 19:03 ч. UTC

Пазарно говорене

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5.06.2026 г., 18:59 ч. UTC

Пазарно говорене

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5.06.2026 г., 18:47 ч. UTC

Пазарно говорене

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5.06.2026 г., 18:34 ч. UTC

Пазарно говорене

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5.06.2026 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5.06.2026 г., 17:50 ч. UTC

Печалби

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5.06.2026 г., 17:27 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5.06.2026 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

5.06.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

5.06.2026 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5.06.2026 г., 15:26 ч. UTC

Пазарно говорене

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5.06.2026 г., 15:25 ч. UTC

Печалби

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5.06.2026 г., 15:16 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

64.2% нагоре

12-месечна прогноза

Среден 34.86 USD 64.2%

Висок 36 USD

Нисък 34 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Arcutis Biotherapeutics Inc през последните 3 месеца.

Настроение

By Acuity

67 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.